Zyversa Therapeutics Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements

Reuters07-17

<a href="https://laohu8.com/S/ZVSA">Zyversa Therapeutics</a> Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements

ZyVersa Therapeutics Inc. has announced that it received a determination letter from The Nasdaq Stock Market LLC indicating the denial of its request to continue listing on The Nasdaq Capital Market. This decision follows the company's non-compliance with the minimum bid price requirements under Nasdaq's Listing Rule 5550(a)(2). Despite appealing the decision and requesting an exception to complete its compliance plan, the Nasdaq Hearings Panel upheld the delisting decision. Consequently, trading of ZyVersa's common stock will be suspended at the opening of trading on July 17, 2025. The company plans to mitigate the impact by applying for trading on the Pink Limited Market under the symbol "ZVSA." This move might pose challenges for stockholders due to a potentially limited market for trading shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-019856), on July 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2552124745?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 00:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552124745","market":"nz","top_or_hot":-1,"title":"Zyversa Therapeutics Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZVSA\">Zyversa Therapeutics</a> Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ZyVersa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced that it received a determination letter from The Nasdaq Stock Market LLC indicating the denial of its request to continue listing on The Nasdaq Capital Market. This decision follows the company's non-compliance with the minimum bid price requirements under Nasdaq's Listing Rule 5550(a)(2). Despite appealing the decision and requesting an exception to complete its compliance plan, the Nasdaq Hearings Panel upheld the delisting decision. Consequently, trading of ZyVersa's common stock will be suspended at the opening of trading on July 17, 2025. The company plans to mitigate the impact by applying for trading on the Pink Limited Market under the symbol \"ZVSA.\" This move might pose challenges for stockholders due to a potentially limited market for trading shares.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-019856), on July 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zyversa Therapeutics Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZyversa Therapeutics Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-17 00:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZVSA\">Zyversa Therapeutics</a> Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ZyVersa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced that it received a determination letter from The Nasdaq Stock Market LLC indicating the denial of its request to continue listing on The Nasdaq Capital Market. This decision follows the company's non-compliance with the minimum bid price requirements under Nasdaq's Listing Rule 5550(a)(2). Despite appealing the decision and requesting an exception to complete its compliance plan, the Nasdaq Hearings Panel upheld the delisting decision. Consequently, trading of ZyVersa's common stock will be suspended at the opening of trading on July 17, 2025. The company plans to mitigate the impact by applying for trading on the Pink Limited Market under the symbol \"ZVSA.\" This move might pose challenges for stockholders due to a potentially limited market for trading shares.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-019856), on July 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZVSA","symbol_name":"ZyVersa Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDLKjgSw:1","article_id":"2552124745","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552124745","pubTimestamp":1752684084,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ZyVersa Therapeutics Inc. has announced that it received a determination letter from The Nasdaq Stock Market LLC indicating the denial of its request to continue listing on The Nasdaq Capital Market. This decision follows the company's non-compliance with the minimum bid price requirements under Nasdaq's Listing Rule 5550. Despite appealing the decision and requesting an exception to complete its compliance plan, the Nasdaq Hearings Panel upheld the delisting decision. Consequently, trading of ZyVersa's common stock will be suspended at the opening of trading on July 17, 2025. The company plans to mitigate the impact by applying for trading on the Pink Limited Market under the symbol \"ZVSA.\" This move might pose challenges for stockholders due to a potentially limited market for trading shares.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZVSA":"ZyVersa Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Zyversa Therapeutics因未达到最低投标价格要求面临纳斯达克退市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZVSA":0.9},"content_text":"Zyversa Therapeutics Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements\n    \n\n        ZyVersa Therapeutics Inc. has announced that it received a determination letter from The Nasdaq Stock Market LLC indicating the denial of its request to continue listing on The Nasdaq Capital Market. This decision follows the company's non-compliance with the minimum bid price requirements under Nasdaq's Listing Rule 5550(a)(2). Despite appealing the decision and requesting an exception to complete its compliance plan, the Nasdaq Hearings Panel upheld the delisting decision. Consequently, trading of ZyVersa's common stock will be suspended at the opening of trading on July 17, 2025. The company plans to mitigate the impact by applying for trading on the Pink Limited Market under the symbol \"ZVSA.\" This move might pose challenges for stockholders due to a potentially limited market for trading shares.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-019856), on July 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552124745","isCrawlerRequest":true}